1. Enhanced Monitoring and the Bad Ad Program

The FDA's Office of Prescription Drug Promotion (OPDP) is actively implementing its 'Bad Ad Program,' which encourages healthcare professionals (HCPs) to monitor and report false or misleading advertising by pharmaceutical companies. Since its launch in May 2010, the program has received over 3,200 reports of misleading advertisements by October 2024, becoming a key tool for promoting voluntary compliance with marketing regulations within the pharmaceutical industry. Recognizing that the FDA cannot individually monitor the numerous conferences, presentations, and informal seminars, the program leverages the expertise of on-site medical professionals to proactively identify and address marketing distortions.

2. GLP-1 Obesity Treatment Market and Crackdown on False Advertising

In the rapidly growing market for obesity treatments (GLP-1 receptor agonists), the FDA has intensified its scrutiny. In the latter half of 2025, the FDA will launch a comprehensive direct-to-consumer (DTC) advertising enforcement initiative, targeting Novo Nordisk (NVO)'s Wegovy (active ingredient: semaglutide) and Eli Lilly (LLY)'s Zepbound (active ingredient: tirzepatide) for advertisements that omitted critical safety information. Specifically, the FDA has issued strong untitled letters and warning letters regarding advertisements in mainstream media and social media that excessively emphasized the efficacy of the drugs while failing to disclose potential side effects or boxed warnings.

3. Inevitable Adjustments to Pharmaceutical Marketing Strategies

With the U.S. pharmaceutical advertising market projected to reach approximately $39 billion in 2025, and digital media advertising accounting for a significant $24.8 billion, regulatory oversight is increasingly focused on digital and media platforms. This means that the OPDP's review process now encompasses not only print materials and websites but also marketing campaigns featuring celebrities or influencers, as well as mentions of the drugs by executives on their personal social media accounts. Consequently, pharmaceutical companies must thoroughly revise their compliance departments' pre-marketing review processes and strengthen internal regulations to prevent substantial penalties associated with off-label promotion.

4. Enhancing Transparency for Investor and Patient Protection

The FDA's actions represent a significant turning point in ensuring patient safety and providing transparent information, addressing the potential for misleading safety perceptions resulting from the intense competition among pharmaceutical companies in the market after the drugs are approved. From an investor perspective, while regulatory actions and requests for corrective measures may temporarily delay marketing campaigns, they are expected to ultimately control the risks of lawsuits and brand damage associated with false or misleading advertising. As a result, companies' compliance capabilities are increasingly recognized as a critical asset that maximizes the value of their pipelines.